샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779742

세계의 세포 리프로그래밍 시장

Cell Reprogramming
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 369 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포 리프로그래밍 시장은 2030년까지 6억 1,160만 달러에 달할 전망

2024년에 3억 9,450만 달러로 추정되는 세계의 세포 리프로그래밍 시장은 2030년에는 6억 1,160만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 7.6%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 mRNA 리프로그래밍 기술은 CAGR 8.4%를 기록하며, 분석 기간 종료시에는 3억 4,190만 달러에 달할 것으로 예측됩니다. 에피솜 리프로그래밍 기술 분야의 성장률은 분석 기간 중 CAGR 7.1%로 추정됩니다.

미국 시장은 1억 750만 달러로 추정, 중국은 CAGR 12.0%로 성장할 것으로 예측

미국의 세포 리프로그래밍 시장은 2024년에 1억 750만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 3,060만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 12.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.8%와 7.3%로 예측됩니다. 유럽에서는 독일이 CAGR 5.0%로 성장할 것으로 예측됩니다.

세계의 세포 리프로그래밍 시장 - 주요 동향과 촉진요인 정리

세포의 리프로그래밍은 재생의료에 어떤 변화를 가져올까?

세포의 리프로그래밍은 재생의료의 획기적인 접근법으로 등장하여 분화된 세포를 다능성 줄기세포로 전환할 수 있게 되었습니다. 이 획기적인 기술은 퇴행성 질환, 장기부전, 유전성 질환을 치료할 수 있는 엄청난 잠재력을 가지고 있습니다. 연구진은 손상된 조직을 복구하고 장기를 재생하기 위해 세포의 정체성을 조작하는 새로운 방법을 모색하고 있으며, 맞춤형 의료에 적용될 것으로 기대됩니다. CRISPR-Cas9와 같은 유전자 편집 기술의 발전은 세포 재프로그래밍의 정확성과 효율성을 더욱 높이고 있습니다. 보다 안전하고 효과적인 초기화 방법의 개발은 임상 적용을 가속화하여 현대 재생 치료의 핵심이 되고 있습니다. 연구가 진행됨에 따라 세포 재프로그래밍 시장은 빠르게 성장하고 있습니다.

세포 재프로그래밍에 대한 수요가 증가하는 이유는 무엇인가?

신경퇴행성 질환, 심혈관 질환, 암과 같은 만성질환의 유병률이 증가함에 따라 혁신적인 치료법에 대한 수요가 증가하고 있습니다. 세포 리프로그래밍은 신체 자체의 세포 메커니즘을 이용하여 기능을 회복시킴으로써 기존 치료법에 대한 대안이 될 수 있습니다. 또한 이식이나 약물 시험을 위해 환자 특이적 세포를 제작하는 능력도 제약회사 및 연구기관의 관심을 높이고 있습니다. 또한 확대되고 있는 조직공학 및 3D 바이오프린팅 분야에서는 세포 리프로그래밍이 신약개발 및 독성시험을 위한 기능적 조직모델 개발에 활용되고 있습니다. 규제 체계가 이러한 새로운 치료법에 대응할 수 있도록 진화함에 따라 임상시험 및 중개 연구에 대한 투자가 증가하고 시장 출시가 가속화될 것으로 예측됩니다.

셀 리프로그래밍 시장을 주도하는 지역은?

북미가 세포 재프로그래밍 시장을 독점하고 있으며, 강력한 연구 자금, 첨단 의료 인프라, 대형 생명공학 기업의 존재가 그 원동력이 되고 있습니다. 특히 미국은 줄기세포 연구와 재생의료의 최전선에 있으며, 세포 재프로그래밍에 대한 획기적인 연구를 진행하고 있는 기관들이 있습니다. 유럽에서도 독일, 영국, 프랑스 등의 국가들이 세포치료 및 재생의료 구상에 많은 투자를 하고 있습니다. 한편, 아시아태평양은 정부 지원 증가, 생명공학 스타트업의 확대, 학계와 업계 관계자들의 협력 관계 증가로 인해 급성장하고 있습니다. 일본과 중국 같은 국가들이 줄기세포 연구에서 큰 진전을 보이고 있으며, 시장 확대에 더욱 박차를 가하고 있습니다.

시장 성장을 가속하는 주요 요인은 무엇인가?

세포 재프로그래밍 시장의 성장은 유전자 편집의 발전, 재생의료에 대한 투자 증가, 맞춤형 의료에 대한 적용 확대 등 여러 요인에 의해 주도되고 있습니다. 신약개발을 위한 질병 특이적 모델을 생성할 수 있게 됨에 따라 의약품 연구개발이 변화하고 있으며, 표적치료제 개발이 가속화되고 있습니다. 또한 인공지능과 머신러닝을 통합하여 데이터 분석을 강화하고, 리프로그래밍 기술을 최적화하고 있습니다. 재생치료에 대한 수요가 증가하고 줄기세포 연구를 둘러싼 윤리적 우려가 줄어들면서 세포 재프로그래밍 시장은 향후 수년간 지속적인 성장을 이룰 것으로 전망됩니다.

부문

기술(mRNA 리프로그래밍 기술, 에피솜 리프로그래밍 기술, 센다이바이러스 기반 리프로그래밍 기술, 기타 기술), 용도(조사 용도, 치료 용도), 최종 용도(연구·학술기관, 바이오테크놀러지·제약 기업)

조사 대상 기업의 예

  • Asgard Therapeutics AB
  • Aspen Neuroscience
  • Astellas Pharma Inc.
  • Autolus Therapeutics
  • Beam Therapeutics
  • bit.bio
  • BlueRock Therapeutics
  • Capricor Therapeutics
  • Cell Reprogramming & Therapeutics LLC
  • Century Therapeutics
  • Colossal Biosciences
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Fate Therapeutics
  • Fujifilm Cellular Dynamics, Inc.
  • Graphite Bio
  • Healios K.K.
  • Intellia Therapeutics
  • Lyell Immunopharma
  • Mogrify Limited

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장과 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.11

Global Cell Reprogramming Market to Reach US$611.6 Million by 2030

The global market for Cell Reprogramming estimated at US$394.5 Million in the year 2024, is expected to reach US$611.6 Million by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. mRNA Reprogramming Technology, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$341.9 Million by the end of the analysis period. Growth in the Episomal Reprogramming Technology segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.5 Million While China is Forecast to Grow at 12.0% CAGR

The Cell Reprogramming market in the U.S. is estimated at US$107.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$130.6 Million by the year 2030 trailing a CAGR of 12.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Cell Reprogramming Market - Key Trends & Drivers Summarized

How Is Cell Reprogramming Transforming Regenerative Medicine?

Cell reprogramming has emerged as a revolutionary approach in regenerative medicine, enabling scientists to convert differentiated cells into pluripotent stem cells. This breakthrough technology holds immense potential for treating degenerative diseases, organ failure, and genetic disorders. Researchers are exploring new ways to manipulate cellular identity to repair damaged tissues and regenerate organs, offering promising applications in personalized medicine. Advancements in gene editing techniques, such as CRISPR-Cas9, have further enhanced the precision and efficiency of cell reprogramming. The development of safer and more effective reprogramming methods is accelerating clinical applications, making it a cornerstone of modern regenerative therapies. As research continues to uncover novel pathways for cellular transformation, the market for cell reprogramming is set for rapid expansion.

Why Is the Demand for Cell Reprogramming Increasing?

The increasing prevalence of chronic diseases, including neurodegenerative conditions, cardiovascular disorders, and cancer, is driving demand for innovative therapeutic approaches. Cell reprogramming offers a viable alternative to traditional treatments by harnessing the body’s own cellular machinery to restore function. The ability to generate patient-specific cells for transplantation and drug testing is also fueling interest among pharmaceutical companies and research institutions. Additionally, the expanding field of tissue engineering and 3D bioprinting is leveraging cell reprogramming to develop functional tissue models for drug discovery and toxicity testing. As regulatory frameworks evolve to accommodate these emerging therapies, increased investment in clinical trials and translational research is expected to accelerate market adoption.

Which Regions Are Leading the Cell Reprogramming Market?

North America dominates the cell reprogramming market, driven by strong research funding, advanced healthcare infrastructure, and the presence of leading biotechnology firms. The United States, in particular, is at the forefront of stem cell research and regenerative medicine, with several institutions conducting groundbreaking studies on cell reprogramming. Europe follows closely, with countries such as Germany, the UK, and France investing heavily in cellular therapies and regenerative medicine initiatives. Meanwhile, the Asia-Pacific region is witnessing rapid growth due to increasing government support, expanding biotech startups, and rising collaborations between academic institutions and industry players. Countries like Japan and China are making significant strides in stem cell research, further propelling market expansion.

What Are the Key Factors Driving Market Growth?

The growth in the cell reprogramming market is driven by several factors, including advancements in gene editing, increasing investment in regenerative medicine, and expanding applications in personalized healthcare. The ability to generate disease-specific models for drug discovery is transforming pharmaceutical R&D, leading to the accelerated development of targeted therapies. Furthermore, the integration of artificial intelligence and machine learning in cell reprogramming research is enhancing data analysis and optimizing reprogramming techniques. As the demand for regenerative treatments rises and ethical concerns surrounding stem cell research diminish, the market for cell reprogramming is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Cell Reprogramming market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming, Other Technologies); Application (Research Application, Therapeutic Application); End-Use (Research and Academic Institutes, Biotechnology and Pharmaceutical Companies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Asgard Therapeutics AB
  • Aspen Neuroscience
  • Astellas Pharma Inc.
  • Autolus Therapeutics
  • Beam Therapeutics
  • bit.bio
  • BlueRock Therapeutics
  • Capricor Therapeutics
  • Cell Reprogramming & Therapeutics LLC
  • Century Therapeutics
  • Colossal Biosciences
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Fate Therapeutics
  • Fujifilm Cellular Dynamics, Inc.
  • Graphite Bio
  • Healios K.K.
  • Intellia Therapeutics
  • Lyell Immunopharma
  • Mogrify Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cell Reprogramming - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthroughs in iPSC Technology Propel Growth of Personalized Medicine Applications
    • Growing Demand for Patient-Derived Cell Models Drives Cell Reprogramming Research
    • Expansion of Drug Discovery and Disease Modeling Markets Boosts Adoption of Reprogramming Techniques
    • Technological Innovations in Gene Editing Strengthen Cell Reprogramming Precision and Efficiency
    • Rising Interest in Anti-Aging and Regenerative Medicine Spurs Scientific Exploration
    • Increased Focus on Cell-Based Therapeutics Fuels Investment in Reprogramming Platforms
    • Advancements in 3D Cell Culture and Organoid Development Enhance Market Potential
    • Emergence of AI and Automation Tools Streamlines Cell Reprogramming Workflows
    • Growing Academic and Commercial Collaborations Drive Translational Research
    • Rising Adoption of Reprogramming Techniques in Toxicology and Safety Screening Expands End-Use Applications
    • Development of Non-Integrating Reprogramming Methods Enhances Clinical Viability
    • Use of Reprogrammed Cells in Rare Disease Research Generates New Opportunities
    • Demand for Personalized Cell Lines in Oncology Accelerates Market Adoption
    • Increasing Government and Private Sector Funding Propels R&D in Cellular Engineering
    • Integration with Synthetic Biology Expands Future Therapeutic Possibilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cell Reprogramming Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cell Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for mRNA Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for mRNA Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for mRNA Reprogramming Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Episomal Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Episomal Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Episomal Reprogramming Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sendai Virus-based Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sendai Virus-based Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Sendai Virus-based Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapeutic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Therapeutic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Therapeutic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Research & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Biotechnology & Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • JAPAN
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • CHINA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • EUROPE
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cell Reprogramming by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • FRANCE
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • GERMANY
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Cell Reprogramming by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • INDIA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Cell Reprogramming by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Cell Reprogramming by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • AFRICA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제